COMMUNIQUÉS West-GlobeNewswire

DBV Technologies participera au prochain congrès EAACI 2025
12/06/2025
Châtillon, France, le 12 juin (22:30 CEST) 2025 DBV Technologies participera au prochain congrès EAACI 2025 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT ; CUSIP : 23306J309), une [...]
DBV Technologies to Participate in Upcoming EAACI Congress 2025
12/06/2025
Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage [...]
Hapbee Is Upgrading U.S. Listing to OTCID to Expand Investor Access and Increase Market Visibility
12/06/2025
Hapbee Also Updates Status of Audited Financial Statements VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies Inc. (TSXV: HAPB | OTC: HAPBF) (“Hapbee” or the “Company”), a leading [...]
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
12/06/2025
Meeting to Reconvene on Wednesday, July 9, 2025 SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making [...]
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
13/06/2025
Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0) 48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1 [...]
First of Its Kind in the Region: KFSHRC Successfully Performs Endoscopic Sleeve Gastroplasty on Kidney Transplant Patient
12/06/2025
RIYADH, Saudi Arabia, June 12, 2025 (GLOBE NEWSWIRE) -- In a medical achievement considered the first of its kind in the region, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has successfully [...]
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
12/06/2025
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
12/06/2025
Company Announcement COPENHAGEN, Denmark; June 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to employees of the [...]
Grant of Warrants
12/06/2025
12 June 2025 Announcement no. 17 Grant of Warrants Copenhagen, Denmark, June 12, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to issue a [...]
Catheter Precision, Inc. Comments on Recent Market Activity
12/06/2025
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, is issuing this press release in [...]
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
12/06/2025
Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“ [...]
Bay Area Lyme Foundation Announces National Winner of the 2025 Emerging Leader Award to Develop a Much-Needed Rapid, Low-Cost, Easy-to-Use Lyme Disease Test
12/06/2025
Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases PORTOLA VALLEY, Calif., June 12, 2025 ( [...]
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
12/06/2025
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML AML patients with diverse mutations, including TP53-mutated/CK and FLT3- [...]
Ipsen - Mai 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
12/06/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
12/06/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 mai 2025
12/06/2025
Nombre total de droits de vote et d’actions composant le capital social au 31 mai 2025 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2025
12/06/2025
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
12/06/2025
GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused [...]
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
12/06/2025
– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed with 67% (29/43) CR [...]

Pages